The "early birds": Natural IgM antibodies and immune surveillance

Histology and Histopathology

Volumn 20, Issue 3, 2005, Pages 927-937

  Vollmers, H Peter ^a   Brandlein S ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Human antibodies; Immune surveillance; Malignancy; Natural IgM antibodies

Indexed keywords

DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN M ANTIBODY; TOLL LIKE RECEPTOR;

ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; APOPTOSIS; CANCER INVASION; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; GENE MUTATION; HUMAN; HUMORAL IMMUNITY; HYBRIDOMA; IMMUNIZATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRECANCER; REVIEW; TUMOR IMMUNITY;

AVES;

EID: 21644466609     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Adderson E.E., Shackelford P.G., Quinn A. and Carroll W.L. (1991). Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. J. Immunol. 147, 1667-1674.
2. Beg A.A. (2002). Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 23, 509-512.
3. Ben-Aissa-Fennira F., Ben Ammar-El Gaaied A., Bouguerra A. and Dellagi K. (1998). IgM antibodies to P1 cytoadhesin of Mycoplasma pneumoniae are part of the natural antibody repertoire expressed early in life. Immunol. Lett. 63, 59-62.
4. Boes M. (2000). Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. 37, 1141-1149.
5. Boes M., Prodeus A.P., Schmidt T., Carroll M.C. and Chen J. (1998). A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188, 2381-2386.
6. Bohn J. (1999). Are natural antibodies involved in tumour defence? Immunol. Lett. 69, 317-320.
7. Brändlein S. and Vollmers H.P. (2004). Natural IgM antibodies, the ignored weapons in tumour immunity. Histol. Histopathol. 19, 897-905.
8. Brändlein S., Lorenz J., Ruoff N., Hensel F., Beyer I., Müller J., Neukam K., Illert B., Eck M., Müller-Hermelink H.K. and Vollmers H.P. (2002). Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum. Antibodies 11, 107-119.
9. Brändlein S., Beyer I., Eck M., Bernhardt W., Hensel F., Müller-Hermelink H.K. and Vollmers H.P. (2003a) CFR-1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res. 63, 2052-2061.
10. Brändlein S., Pohle T., Ruoff N., Wozniak E., Müller-Hermelink H.K. and Vollmers H.P. (2003b). Natural IgM antibodies and immunosurveillance. Mechanisms against epithelial cancer cells in humans. Cancer Res. 63, 7995-8005.
11. Brändlein S., Pohle T., Vollmers C., Wozniak E., Ruoff N., Müller-Hermelink H.K. and Vollmers H.P. (2004). CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol. Rep. 11, 777-784
12. Brezinschek H.P., Brezinschek R.I. and Lipsky P.E. (1995). Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J. Immunol. 155, 190-202.
13. Burnet F.M. (1964). Immunological factors in the process of carcinogenesis. Br. Med. Bull. 20, 154-158.
14. Burnet F.M. (1970). The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27.
15. Casali P. and Notkins A.L. (1989). CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol. Today 10, 364-368.
16. Cedar H. and Bergman Y. (1999). Developmental regulation of immune system gene rearrangement. Curr. Opin. Immunol. 11, 64-69.
17. Constantinescu A. and Schlissel M.S. (1997). Changes in locus-specific V(D)J recombinase activity induced by immunoglobulin gene products during B cell development. J. Exp. Med. 185, 609-620.
18. Dunn G.P., Bruce A.T., Ikeda H., Old L.J. and Schreiber R.D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 961-998.
19. Dunn G.P., Old L.J. and Schreiber R.D. (2004). The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360.
20. Edelman G.M. and Poulik M.D. (1961). Studies on structural units of the γ-globulins. J. Exp. Med. 113, 867-884.
21. Egea G., Franci C., Gambus G., Lesuffleur T., Zweibaum A., and Real F.X. (1993). cis-Golgi resident proteins and O-glycans are abnormally compartmentalized in the RER of colon cancer cells. J. Cell Sci. 105, 819-830.
22. Ehrlich P. (1900a). The general significance of the side-chain theory, and its importance in biology and therapy. Special Pathol. Therapy 8, 1898-1901, 163-185.
23. Ehrlich P. (1900b). On immunity with special reference to cell life. Proc. R. Soc. Lond. (Biol.) 66, 424-428.
24. Ehrlich P. (1909). Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 5, 273-290.
25. Fearon D.T. and Locksley R.M. (1996). The instructive role of innate immunity in the acquired immune response. Science 272, 50-53.
26. Felton L.D. and Bailey G.H. (1926). Biologic significance of the soluble specific substances of pneumococci. J. Inf. Dis. 38, 131-144.
27. Gabrilovich D. and Pisarev V. (2003). Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets. 4,525-536.
28. Garcia-Lora A., Algarra I. and Garrido F. (2003). MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell Physiol. 195, 346-355.
29. Gellert M. (1997). Recent advances in understanding V(D)J recombination. Adv. Immunol. 64, 39-64.
30. Griffiths A.D. and Duncan A.R. (1998). Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol. 9, 102-108.
31. Hanisch F.G., Stadie T.R., Deutzmann F. and Peter Katalinic J. (1996). MUC1 glycoforms in breast cancer-cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation. Eur. J. Biochem. 236, 318-327.
32. Heidelberger M. and Avery O.T. (1923). The soluble specific substance of Pneumococcus. J. Exp. Med. 38, 73-79.
33. Hensel F., Hermann R., Schubert C., Abé N., Schmidt K., Franke A., Shevchenko A., Mann M., Müller-Hermelink H.K. and Vollmers H.P. (1999a). Characterisation of glycosylphosphatidylinositol-linked molecule CD55/Decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res. 59, 5299-5306.
34. Hensel F., Knorr C., Hermann R., Krenn V., Muller-Hermelink H.K. and Vollmers H.P. (1999b). Mitogenic autoantibodies in Helicobacter pylori-associated stomach cancerogenesis. Int. J. Cancer 81, 229-235.
35. Hensel F., Brandlein S., Eck M., Schmidt K., Krenn V., Kloetzer A., Bachi A., Mann M., Muller-Hermelink H.K. and Vollmers H.P. (2001a). A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab. Invest. 81, 1097-1108.
36. Hensel F., Hermann R., Brandlein S., Krenn V., Schmausser B., Geis S., Muller-Hermelink H.K. and Vollmers H.P. (2001b). Regulation of the New Coexpressed CD55 (Decay-Accelerating Factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab. Invest. 81, 1553-1563.
37. Huang D.F., Olee T., Masuho Y., Matsumoto Y., Carson D.A. and Chen P.P. (1992). Sequence analyses of three immunoglobulin G anti-virus antibodies reveal their utilization of autoantibody-related immunoglobulin Vh genes, but not V lambda genes. J. Clin. Invest. 90, 2197-2208.
38. Janeway C.A. Jr. (1989). Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13.
39. Janeway C.A. Jr and Medzhitov R. (2002). Innate immune recognition. Annu. Rev. Immunol. 20, 197-216.
40. Karsten U., Diotel C., Klich G., Paulsen H., Goletz S., Müller S. and Hanisch F.G. (1998). Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Res. 58, 2541-2549.
41. Landsteiner K. (1901). Über Agglutinationserscheinungen normalen menschlichen Blutes. Wien. Klein. Wochenschr. 14, 1132-1134.
42. Lewis S.M. (1994). The mechanism of V(D)J joining: lessons from molecular, immunological, and comparative analyses. Adv. Immunol. 56, 27-150.
43. Lloyd K.O. and Old L.J. (1989). Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Res. 49, 3445-51.
44. MacPherson G., Kushnir N. and Wykes M. (1999). Dendritic cells, B cells and the regulation of antibody synthesis. Immunol. Rev. 172, 325-334.
45. Marchalonis J.J., Kaveri S., Lacroix-Desmazes S. and Kazatchkine M.D. (2002). Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system. FASEB J. 16, 842-848.
46. Marrack J.R. (1934, 1938). The chemistry of antigens and antibodies. MCR Special Report Series, No. 230 (1938) and No. 194 (1934).
47. Martin F. and Kearney J.F. (2001). B1 cells: similarities and differences with other B cell subsets. Curr. Opin. Immunol. 13, 195-201.
48. Medzhitov R. (2001). Toll-like receptors and innate immunity. Nature Rev. Immunol. 1, 135-145.
49. Medzhitov R. and Janeway C.A. Jr (1997). Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 9, 4-9.
50. Medzhitov R. and Janeway C. Jr (2000). The Toll receptor family and microbial recognition. Trends Microbiol. 8, 452-456.
51. Moretta L., Biassoni R., Bottino C., Mingari M.C. and Moretta. A. (2002). Natural killer cells: a mystery no more. Scand. J. Immunol. 55, 229-232.
52. Numberger T., Brunner F., Kemmerling B. and Piater L. (2004). Innate immunity in plants and animals: striking similarities and obvious differences. Immunol. Rev. 198, 249-266.
53. Ochsenbein A.F. and Zinkernagel R.M. (2000). Natural antibodies and complement link innate and acquired immunity. Immunol. Today 21, 624-630.
54. Ochsenbein A.F., Fehr T., Lutz C., Suter M., Brombacher F., Hengartner H. and Zinkernagel R.M. (1999). Control of early viral and bacterial distribution and disease by natural antibodies. Science 286, 2156-2159.
55. Papavasiliou F., Jankovic M., Gong S. and Nussenzweig M.C. (1997). Control of immunoglobulin gene rearrangements in developing B cells. Curr. Opin. Immunol. 9, 233-238.
56. Parkin J. and Cohen B. (2001). An overview of the immune system. Lancet 357, 1777-1789.
57. Pohle T., Brändlein S., Ruoff N., Müller-Hermelink H.K. and Vollmers H.P. (2004). Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res. 64, 3900-3906.
58. Porter R.R. (1959). The hydrolysis of rabbit γ-globulin and antibodies with crystalline papain. Biochem. J. 73, 119-126.
59. Preuss K.D., Zwick C., Bormann C., Neumann F. and Pfreundschuh M. (2002). Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev. 188, 43-50.
60. Rothenberg E.V. (2000). Stepwise specification of lymphocyte developmental lineages. Curr. Opin. Genet. Dev. 10, 370-379.
61. Schatz D.G., Oettinger M.A. and Schlissel M.S. (1992). V(D)J recombination: molecular biology and regulation. Annu. Rev. Immunol. 10, 359-383.
62. Silverman G.J. and Lucas A.H. (1991). Variable region diversity in human circulating antibodies specific for the capsular polysaccharide of Haemophilus influenzae type b. Preferential usage of two types of VH3 heavy chains. J. Clin. Invest. 88, 911-920.
63. Thomas L. (1959). Discussion. In: Cellular and humoral aspects of the hypersensitive states, H.S. Lawrence (ed). Hoeber-Harper. New York. pp 529-532.
64. Thomas L. (1982). On immunosurveillance in human cancer. Yale L. Biol. Med. 55, 329-333.
65. Turner G.A. (1992). N-glycosylation of serum proteins in disease and its investigation using lectins. Clin. Chim. Acta 208, 149-171.
66. Ulvestad E., Kanestrom A., Sonsteby L.J., Jureen R., Omland T., Edvardsen B., Lundervik J., Kristoffersen E. and van Dam A.P. (2001). Diagnostic and biological significance of anti-p41 IgM antibodies against Borrelia burgdorferi. Scand. J. Immunol. 53, 416-421.
67. Vollmers H.P. and Brändlein S. (2002). Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Hum Antibodies 11, 131-142.
68. Vollmers H.P., O'Connor R., Müller J., Kirchner T. and Müller-Hermelink H.K. (1989). SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res. 49, 2471-2476.
69. Vollmers H.P., Dämmrich J., Ribbert H., Wozniak E. and Müller-Hermelink H.K. (1995). Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76, 550-558.
70. Vollmers H.P., Zimmermann U., Krenn V., Timmermann W., Illert B., Hensel F., Hermann R., Thiede A., Wilhelm M., Ruckle-Lanz H., Reind L. and Muller-Hermelink H.K. (1998). Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol. Rep. 5, 549-552.
71. Zitvogel L. (2002). Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J. Exp. Med. 195, 9-14.